Global Biopharmaceutical Contract Manufacturing Market to Reach US$ 15,467.8 Mn by 2027 - Future Market Insights

Global Biopharmaceutical Contract Manufacturing Market to Reach US$ 15,467.8 Mn by 2027 - Future Market Insights

Monoclonal Antibodies to Remain Largest and Most Lucrative Segment by Product Type in the Global Biopharmaceutical Contract Manufacturing Market | FMI

PR Newswire

VALLEY COTTAGE, New York, September 12, 2017

VALLEY COTTAGE, New York, September 12, 2017 /PRNewswire/ --

A new study on the global biopharmaceutical contract manufacturing market by FMI discusses some interesting aspects of the differentiating strategies of key market players. Top biomanufacturing companies in North America and Europe are focussing on market collaborations and agreements as key business strategies for growth and expansion across the globe. These companies are also acquiring small scale biopharmaceuticals companies in the Asia Pacific region to strengthen their market presence. FMI presents several useful insights and a comprehensive revenue forecast of the global biopharmaceutical contract manufacturing market in a new report titled "Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012-2016 and Opportunity Assessment 2017-2027" along with information on the factors influencing revenue growth of the market over a 10 year assessment period from 2017 to 2027.

     (Logo: http://photos.prnewswire.com/prnh/20161020/430874LOGO )

The global biopharmaceutical contract manufacturing market is estimated to be valued at US$ 5,625.0 Mn by the end of 2017 and this is expected to increase to US$ 15,467.8 Mn by the end of 2027, registering a CAGR of 10.6% in terms of value over the forecast period.

Global Market Research Report Overview on Biopharmaceutical Contract Manufacturing@  https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market

Global Biopharmaceutical Contract Manufacturing Market: Regional Forecast 

The global biopharmaceutical contract manufacturing market has been studied across the key regions of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is the largest regional market, estimated to be valued at US$ 5,039.3 Mn by 2027 end, with a CAGR of 9.8%. APEJ is the second largest market for biopharmaceutical contract manufacturing, with a growth rate of 12.2% anticipated during the 10 year forecast period.

Global Biopharmaceutical Contract Manufacturing Market: Forecast by Platform 

The report segments the global biopharmaceutical contract manufacturing market on the basis of Platform into Mammalian and Microbial. Mammalian is the largest segment by platform, which is estimated to represent US$ 3,857.2 Mn or 68.6% share of the total market in 2017 and is projected to reach US$ 12,534.5 Mn or 81.0% share by 2027 end, expanding at a CAGR of 12.5% over the forecast period.

Global Biopharmaceutical Contract Manufacturing Market: Forecast by Product Type 

In terms of product type, the global biopharmaceutical contract manufacturing market is segmented into Growth Factors, Interferons, Monoclonal Antibodies, Recombinant Hormones, Vaccines, Insulin, and Others. Monoclonal Antibodies is the largest segment by product type, with revenues estimated to cross US$ 8,100 Mn by the end of the forecast period and a CAGR of 11.3%.

View Report Table of Contents, Figures, and Tables@ https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market/toc

Global Biopharmaceutical Contract Manufacturing Market: Forecast by Application 

The global biopharmaceutical contract manufacturing market is segmented on the basis of application into Clinical and Commercial. The Commercial segment will dominate the global market, with revenues in excess of US$ 12,000 Mn expected to be recorded by the end of 2027 resulting in a CAGR of 11.0%.

Global Biopharmaceutical Contract Manufacturing Market: Forecast by Therapeutic Area 

On the basis of therapeutic area, the global biopharmaceutical contract manufacturing market is segmented into Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, and Others. Oncology is the largest segment by therapeutic area, expected to be valued at US$ 1,111.1 Mn by the end of 2017. Oncology is also the most lucrative segment. Autoimmune Diseases is the second largest segment by therapeutic area with a market attractiveness index of 1.3.

Global Biopharmaceutical Contract Manufacturing Market: Competitive Landscape 

The report features some of the leading companies operating in the global biopharmaceutical contract manufacturing market. Companies profiled include Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea, Inc.

A sample of this report is available upon request@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2982

About Us  

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): +44(0)20-7692-8790
Sales: sales@futuremarketinsights.com


Websitehttp://www.futuremarketinsights.com


Voltar noticias em Inglês